Biofrontera, Inc. (BFRI)

Over the past six months, Biofrontera regained compliance with Nasdaq's listing requirements. The FDA accepted the sNDA filing for Ameluz® PDT in superficial basal cell carcinoma. The U.S. Patent Office ruled Sun Pharma's patent claims unpatentable. Positive Phase 2b results supported Ameluz® Photodynamic Therapy development for acne vulgaris. The company reported record fourth quarter and full year 2025 financial results, with revenues expected to grow by approximately 11% to 13%.

Biofrontera's fourth quarter is crucial for revenue performance. Increased Ameluz® dosing per treatment has the potential to lead to higher sales volumes. Revenue growth is anticipated due to new treatment indications for Basal Cell Carcinoma and Actinic Keratoses in 2026 and 2027, along with an expanded sales force and favorable reimbursement policies for Ameluz®.

Biofrontera, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing dermatological products, particularly photodynamic therapy (PDT). Their flagship product is Ameluz®, used with RhodoLED® lamps for treating actinic keratoses. They are also exploring Ameluz®-PDT for non-melanoma skin cancers and acne. Biofrontera previously commercialized Xepi® but divested its U.S. license to focus on its PDT platform.

Biofrontera, Inc. is based in the U.S., with headquarters in Woburn, Massachusetts, and focuses on commercialization and regulatory activities for products like Ameluz® in the United States. Biofrontera Discovery, a wholly-owned subsidiary in Germany, handles global functions such as clinical development, regulatory affairs, quality, pharmacovigilance, and manufacturing.

Biofrontera emphasizes customer relations and builds relationships with healthcare professionals. They support doctors with PDT knowledge through e-learning and workshops, participate in dermatological congresses, and assist with practice organization. Biofrontera supports researchers and universities in Investigator Initiated Trials to optimize PDT application and improve patient care. There have been no significant negative events affecting the brand reputation in the past year.

Biofrontera's stock is held by institutional shareholders (20.07%), insiders (27.76%), and retail investors (52.17%). Major institutional owners include Rosalind Advisors, Inc., AIGH Capital Management LLC, and Vanguard Group Inc. Wilhelm Konrad Thomas Zours is the largest individual shareholder, and Biofrontera AG retains a significant stake.